Table 2. Results of the combined screening procedure.
| TOTAL CASES | Solid Cancers | Hematologic Cancers | |
|---|---|---|---|
| 860 | 386 (45%) | 474 (55%) | |
| Symptoms potentially SARS-COV-2 related 1 | |||
| Present | 112 (13%) | 52 (13,5%) | 60 (13%) |
| Absent | 748 (87%) | 334 (86,5%) | 414 (87%) |
| Nasopharyngeal Swabs (NPS) SARS-COV-2 | |||
| Total number | 2955 | 1692 | 1263 |
| Median NPS/patient | 4 (1–9) | 4 (1–9) | 3 (1–9) |
| Pt Positive | 1 (<1%) | 1 (<1%) | 0 (0%) |
| SARS-COV-2 IgG/IgM Rapid Test | |||
| Total Number | 860 | 386 | 474 |
| Positive | 14 (1,62%) | 6 (1,55%) | 8 (1,7%) |
| IgG and IgM positive | 7 | 3 | 4 |
| Only IgG positive | 1 | 1 | 0 |
| Only IgM positive | 4 | 2 | 4 |
1 Clinical Manifestations that could be attributed to SARS-CoV-2 disease: fever, cough, dyspnea, fatigue, headache, myalgia, vomiting, diarrhea and neurological manifestations (anosmia, ageusia).